Subjective cognitive decline (SCD) G30.9
Conditions
Interventions
Group 1: a) Cognitively healthy participants without a family history or personal experience with Alzheimer's dementia
Baseline: questionnaire survey and optional narrative interview
Optional follow-u
Baseline: questionnaire survey and optional narrative interview
Follow-up after 6 months: questionnaire survey
Optional after 1 year: narrative interview
Group 3: c) N=50 participants with subjective
Baseline: questionnaire survey and optional narrative interviews
Follow-up after 6 months: questionnaire survey
Optional after 1 year: narrative interview
Group 4: d) N=30 Participants with newly dia
Baseline: questionnaire survey and optional narrative interview
Follow-up after 6 months: questionnaire survey
Optional after 1 year: narrative interview
Group 5: e) General population
Cross-sectiona
Spain, N=1,000
Switzerland, N=750).
Sponsors
Rheinische Friedrich-Wilhelms-Universität Bonn, Center for Life Ethics
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: ? Written informed consent ? Local language skills that allow all surveys/interviews to be conducted. ? Group a: none ? Group b additionally: - Knowledge of physician-recorded diagnosis of Alzheimer's disease in at least one 1st degree relative (mother, father or sibling) or - Knowledge of the proband about an ApoE-e3/e4 or ApoE-e4/e4 gene carrier status. ? Group c and d additionally: - Self-experienced persistent deterioration of cognitive abilities compared with a previously normal state and unrelated to an acute event. - Unremarkable age-, sex-, and education-adjusted performance on standardized cognitive Tests used to classify mild cognitive impairment (MCI) or Alzheimer's disease (AD) prodromes ? Group e: none
Exclusion criteria
Exclusion criteria: ? Group a additionally: - Presence of mild cognitive impairment, early-stage Alzheimer's disease, or dementia. - Moderate to severe depressive disorder; Hospital Anxiety and Depression Scale (HADS) score > 10 points - Close person with Alzheimer’s disease - (Previous) visit to Alzheimer's prevention centre or a comparable institution - Individuals with a known ApoE-e3/e4 or ApoE-e4/e4 gene carrier status ? Group b additionally: - Presence of mild cognitive impairment, early-stage Alzheimer's disease, or dementia. - Moderate to severe depressive disorder; Hospital Anxiety and Depression Scale (HADS) score > 10 points ? Group c and d additionally: - Presence of mild cognitive impairment, early-stage Alzheimer's disease, or dementia. - Moderate to severe depressive disorder; Hospital Anxiety and Depression Scale (HADS) score > 10 points - Subjective deterioration of cognitive abilities may be due to a psychiatric or neurological disorder (other than Alzheimer's disease), a medical disorder, medications, or drug use. Group e: none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The overarching goal of PreTAD is to identify individual needs and different perspectives on the risk estimation of Alzheimer's dementia, as well as to assess the impact of the paradigm shift in medicine at the individual, linguistic, legal, and societal levels. | — |
Secondary
| Measure | Time frame |
|---|---|
| Development of an empirically based ethically, linguistic and legally informed framework for the risk estimation of Alzheimer's dementia. | — |
Countries
Germany, Spain, Switzerland
Contacts
Public ContactConstanze Hübner
Rheinische Friedrich-Wilhelms-Universität Bonn, Center for Life Ethics
Outcome results
None listed